(NASDAQ: SNDX) Syndax Pharmaceuticals's forecast annual revenue growth rate of 107.06% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Syndax Pharmaceuticals's revenue in 2025 is $43,722,000.On average, 4 Wall Street analysts forecast SNDX's revenue for 2025 to be $10,170,808,472, with the lowest SNDX revenue forecast at $6,196,276,802, and the highest SNDX revenue forecast at $12,357,274,151. On average, 4 Wall Street analysts forecast SNDX's revenue for 2026 to be $19,413,767,301, with the lowest SNDX revenue forecast at $13,752,103,299, and the highest SNDX revenue forecast at $23,898,818,485.
In 2027, SNDX is forecast to generate $34,348,592,787 in revenue, with the lowest revenue forecast at $26,620,499,297 and the highest revenue forecast at $40,915,562,000.